SILO PHARMA, INC. Research and Development Expense
SILO PHARMA, INC. (SILO) reported Research and Development Expense of $298.42 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- SILO PHARMA, INC. research and development expense for the quarter ending 2026-06-30 was $298.42K, a 58.39% decline year-over-year.
- SILO PHARMA, INC. research and development expense for the quarter ending 2026-03-31 was $1.01M, a 70.59% increase year-over-year.
- SILO PHARMA, INC. research and development expense for the quarter ending 2025-12-31 was $306.00K, a 71.55% decline year-over-year.
- SILO PHARMA, INC. research and development expense for the quarter ending 2025-09-30 was $543.62K, a 5.04% increase year-over-year.
- SILO PHARMA, INC. research and development expense for fiscal 2023 was $845.09K, a 34.31% decline from fiscal 2022.
- SILO PHARMA, INC. research and development expense for fiscal 2022 was $1.29M, a 85.39% increase from fiscal 2021.
- SILO PHARMA, INC. research and development expense for fiscal 2021 was $693.91K, a 2543.47% increase from fiscal 2020.
- SILO PHARMA, INC. research and development expense for fiscal 2020 was $26.25K.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $298.42K 10-Q · filed 2026-08-13 | $1.31M 10-Q · filed 2026-08-13 | $1.62M derived: sum of 3 quarters · filed 2026-08-13 | $2.16M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $1.01M 10-Q · filed 2026-05-14 | $1.32M derived: sum of 2 quarters · filed 2026-05-14 | $1.86M derived: sum of 3 quarters · filed 2026-05-14 | $2.58M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $306.00K derived: POS AM 12 month − 10-Q 9 month · filed 2026-04-14 | $849.62K derived: sum of 2 quarters · filed 2026-04-14 | $1.57M derived: sum of 3 quarters · filed 2026-08-13 | $2.16M POS AM · filed 2026-04-14 |
| 2025-09-30 | $543.62K 10-Q · filed 2025-11-13 | $1.26M derived: sum of 2 quarters · filed 2026-08-13 | $1.85M 10-Q · filed 2025-11-13 | $2.93M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $717.25K 10-Q · filed 2026-08-13 | $1.31M 10-Q · filed 2026-08-13 | $2.39M derived: sum of 3 quarters · filed 2026-08-13 | $2.90M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $593.96K 10-Q · filed 2026-05-14 | $1.67M derived: sum of 2 quarters · filed 2026-05-14 | $2.19M derived: sum of 3 quarters · filed 2026-05-14 | $2.58M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $1.08M derived: POS AM 12 month − 10-Q 9 month · filed 2026-04-14 | $1.59M derived: sum of 2 quarters · filed 2026-04-14 | $1.99M derived: sum of 3 quarters · filed 2026-04-14 | $2.37M POS AM · filed 2026-04-14 |
| 2024-09-30 | $517.55K 10-Q · filed 2025-11-13 | $910.37K derived: sum of 2 quarters · filed 2025-11-13 | $1.29M 10-Q · filed 2025-11-13 | $1.57M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $392.82K 10-Q · filed 2025-08-13 | $774.89K 10-Q · filed 2025-08-13 | $1.05M derived: sum of 3 quarters · filed 2025-08-13 | $1.22M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $318.24K 10-Q · filed 2025-05-09 | $655.21K derived: sum of 2 quarters · filed 2025-05-09 | $829.70K derived: sum of 3 quarters · filed 2025-05-09 | $960.42K derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $336.96K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $511.46K derived: sum of 2 quarters · filed 2025-03-28 | $642.18K derived: sum of 3 quarters · filed 2025-03-28 | $845.09K 10-K · filed 2025-03-28 |
| 2023-09-30 | $174.50K 10-Q · filed 2024-11-12 | $305.21K derived: sum of 2 quarters · filed 2024-11-12 | $508.13K 10-Q · filed 2024-11-12 | $1.14M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $130.72K 10-Q · filed 2024-08-13 | $333.63K 10-Q · filed 2024-08-13 | $968.32K derived: sum of 3 quarters · filed 2024-08-13 | $1.34M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $202.91K 10-Q · filed 2024-05-13 | $837.60K derived: sum of 2 quarters · filed 2024-05-13 | $1.21M derived: sum of 3 quarters · filed 2024-05-13 | $1.32M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $634.68K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $1.01M derived: sum of 2 quarters · filed 2024-03-25 | $1.12M derived: sum of 3 quarters · filed 2024-03-25 | $1.29M 10-K · filed 2024-03-25 |
| 2022-09-30 | $375.80K 10-Q · filed 2023-11-13 | $481.47K derived: sum of 2 quarters · filed 2023-11-13 | $651.75K 10-Q · filed 2023-11-13 | $1.13M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $105.68K 10-Q · filed 2023-08-11 | $275.95K 10-Q · filed 2023-08-11 | $751.90K derived: sum of 3 quarters · filed 2023-08-11 | $822.42K derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $170.28K 10-Q · filed 2023-05-12 | $646.23K derived: sum of 2 quarters · filed 2023-05-12 | $716.74K derived: sum of 3 quarters · filed 2023-05-12 | $815.59K derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $475.95K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $546.46K derived: sum of 2 quarters · filed 2023-03-24 | $645.31K derived: sum of 3 quarters · filed 2023-03-24 | $693.91K 10-K · filed 2023-03-24 |
| 2021-09-30 | $70.51K 10-Q · filed 2022-11-10 | $169.36K derived: sum of 2 quarters · filed 2022-11-10 | $217.96K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $98.85K 10-Q · filed 2022-08-01 | $147.45K 10-Q · filed 2022-08-01 | ||
| 2021-03-31 | $48.60K 10-Q · filed 2022-05-13 | |||
| 2020-12-31 | $26.25K 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |